Renata boeck biography sampler
•
The ECFS Awards at European CF Conferences
Updated: 11 June 2024
The ECFS Award
The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis. The winner of the award is invited to present a lecture at the Opening Plenary of the annual ECFS conference in June.
ECFS Members are cordially invited to nominate a candidate for this award. The deadline for proposals is 01 March 2023.
Proposals, accompanied by a detailed motivation and curriculum vitae of the candidate are to be mailed to the ECFS Executive Director, Christine Dubois.
The Gerd Döring Award
The Gerd Döring Award is given annually to honour an exceptional early career young European scientist. The Award, a monetary donation of 5,000 euro to support research, is presented at the Opening Plenary of the annual ECFS conference.
The award is primarily judged (80%) on a paper published in the previous 3 calendar years which has made a significant impact on the understanding or treatment of Cystic Fibrosis. Personal motivation and CV will make a 20% contribution to the scoring.
The award is open to PhD students and post-doctoral researchers with up to a ma
•
Abstract
Introduction
Cystic Fibrosis (CF) is a genetic disease due to loss-of-function mutations of the CFTR channel. F508del is the most frequent mutation (70% of alleles in Italy), while other mutations have much lower frequency. Among them, G85E (0.4% frequency globally, 1.13% in Italy) emerges as a mutation characterized by a severe CFTR folding and trafficking defect.
Methods
To investigate the pharmacological responsiveness of the G85E-CFTR variant, we performed a functional and biochemical characterization in heterologous expression systems and ex vivo models based on patient-derived human nasal epithelial cells (HNEC).
Results
Our study demonstrated that treatment of primary airway cells with elexacaftor and tezacaftor causes a significant (although modest) rescue of CFTR function, that reaches 15%–25% of the activity measured in non-CF epithelia. A detrimental effect of chronic treatment with ivacaftor, further limiting G85E rescue, was also observed. A higher rescue of CFTR function, up to 25%–35% of the normal CFTR activity, with no evidence of negative effects upon chronic potentiator treatment, can be achieved by combining elexacaftor with ARN23765, a novel type 1 corrector endowed with very high potency. Importantly, dose-response relationships suggest t
•
High-resolution carbon cycling data flight 2019 end up 2021 slow at outrage Austrian long-term ecosystem enquiry sites
Marco M. Lehmann, Josie Geris, Ilja van Meerveld, Daniele Penna, Youri Rothfuss, Matteo Verdone, Pertti Ala-Aho, Matyas Arvai, Alise Babre, Philippe Balandier, Fabian Bernhard, Lukrecija Butorac, Simon Damien Carrière, Natalie C. Ceperley, Zuosinan Chen, Alicia Correa, Haoyu Diao, David Dubbert, Maren Dubbert, Fabio Ercoli, Marius G. Floriancic, Missionary E. Gimeno, Damien Gounelle, Frank Hagedorn, Christophe Hissler, Frédéric Huneau, Alberto Iraheta, Tamara Jakovljević, Nerantzis Kazakis, Zoltan Composer, Karl Knaebel, Johannes Kobler, Jiří Kocum, Charlotte Koeber, Gerbrand Koren, Angelika Kübert, Dawid Kupka, Samuel Straight Gall, Aleksi Lehtonen, Clockmaker Leydier, Philippe Malagoli, Francesca Sofia Manca di Metropolis, Chiara Marchina, Núria Martínez-Carreras, Nicolas Martin-StPaul, Hannu Marttila, Aline Meyer Oliveira, Gaël Monvoisin, Natalie Orlowski, Kadi Palmik-Das, Aurel Persoiu, Andrei Popa, Egor Prikaziuk, Cécile Quantin, Katja T. Rinne-Garmston, Clara Rohde, Martin Sanda, Matthias Saurer, Daniel Cartoonist, Michael Libber Stockinger, Christine Stumpp, Jean-Stéphane Venisse, Lukas Vlcek, Stylia